California-based Intarcia Therapeutics raised a combined $210 million to initiate a global Phase III program for a once-yearly, injection-free treatment for Type 2 diabetes. Its investors include New Enterprise Associates, Venrock, New Leaf Venture...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)